| Drug General Information |
| Drug ID |
D0O1LD
|
| Former ID |
DNC002374
|
| Drug Name |
ZSTK474
|
| Drug Type |
Small molecular drug
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1],
[2]
|
|---|
| Therapeutic Class |
Anticancer Agents
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H21F2N7O2
|
| InChI |
InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2
|
| InChIKey |
HGVNLRPZOWWDKD-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
16750771, 23750314, 26746633, 57376964, 77748024, 85756851, 85866113, 87225800, 99373532, 99436967, 103659086, 104149574, 109693182, 118049488, 123044197, 123051054, 123393012, 124756978, 125163783, 126579125, 126634934, 126666954, 126726470, 131480747, 134964393, 135684958, 135686132, 135686133, 135686154, 135686155, 135698920, 135727481, 136367276, 136367715, 137020279, 141089178, 143496971, 152234895, 152258832, 152344015, 160647683, 160820616, 161004407, 162011844, 162037416, 162202601, 163091161, 163379788, 163642384, 164043531
|
| Target and Pathway |
| Target(s) |
Phosphoinositide 3 kinase |
Target Info |
Modulator |
[1]
|
|---|
|
KEGG Pathway
|
Inositol phosphate metabolism
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Phosphatidylinositol signaling system
|
|
Sphingolipid signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Apoptosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
Jak-STAT signaling pathway
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Cholinergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Regulation of actin cytoskeleton
|
|
Insulin signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Aldosterone-regulated sodium reabsorption
|
|
Carbohydrate digestion and absorption
|
|
Bacterial invasion of epithelial cells
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Amoebiasis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Measles
|
|
Influenza A
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Colorectal cancer
|
|
Renal cell carcinoma
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Chronic myeloid leukemia
|
|
Acute myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
PathWhiz Pathway
|
Inositol Metabolism
|
|
Phosphatidylinositol Phosphate Metabolism
|
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
PI3K Cascade
|
|
GPVI-mediated activation cascade
|
|
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
|
PI3K events in ERBB4 signaling
|
|
PIP3 activates AKT signaling
|
|
GAB1 signalosome
|
|
PI3K events in ERBB2 signaling
|
|
PI3K/AKT activation
|
|
Role of phospholipids in phagocytosis
|
|
Tie2 Signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
DAP12 signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
Nephrin interactions
|
|
Costimulation by the CD28 family
|
|
CD28 dependent PI3K/Akt signaling
|
|
G beta:gamma signalling through PI3Kgamma
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling events
|
|
VEGFA-VEGFR2 Pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Constitutive Signaling by EGFRvIII
|
|
PI-3K cascade:FGFR1
|
|
PI-3K cascade:FGFR2
|
|
PI-3K cascade:FGFR3
|
|
PI-3K cascade:FGFR4
|
|
Interleukin receptor SHC signaling
|
|
Regulation of signaling by CBL
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Serotonin HTR1 Group and FOS Pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
Insulin Signaling
|
|
IL-4 Signaling Pathway
|
|
Copper homeostasis
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Transcriptional activation by NRF2
|
|
IL1 and megakaryotyces in obesity
|
|
Signaling by ERBB4
|
|
Signaling by ERBB2
|
|
Fc epsilon receptor (FCERI) signaling
|
|
PI Metabolism
|
|
Interleukin-2 signaling
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
Signaling by SCF-KIT
|
|
DAP12 interactions
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
PIP3 activates AKT signaling
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSLP Signaling Pathway
|
|
Regulation of Microtubule Cytoskeleton
|
|
TSH signaling pathway
|
|
SREBP signalling
|
|
TCR signaling
|
|
Signaling by PDGF
|
|
Signaling by Insulin receptor
|
|
Signaling by FGFR
|
|
Signaling by EGFR
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Nephrin interactions
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
GPVI-mediated activation cascade
|
|
GPCR downstream signaling
|
|
Costimulation by the CD28 family
|
|
Cell surface interactions at the vascular wall
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Angiogenesis
|
|
Regulation of toll-like receptor signaling pathway
|
|
AMPK Signaling
|
| References |
| REF 1 | Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 2013 Oct;15(10):1172-83. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7965). |
|---|
